Today: 13 June 2026
RELX share price dips in London as buyback rolls on and tariff jitters linger
20 January 2026
1 min read

RELX share price dips in London as buyback rolls on and tariff jitters linger

London, Jan 20, 2026, 08:45 GMT — Regular session

  • RELX shares slipped in early London trading while European equities remained under pressure
  • Fresh filings have put the company’s steady buyback pace back in the spotlight
  • Investors are now focused on February results as their next key catalyst

RELX (REL.L) shares slipped 0.3% to 3,005 pence by 0845 GMT, as European stocks edged lower amid fresh U.S. tariff concerns.

The information and analytics group is typically seen as a defensive stock in the FTSE 100, yet it hasn’t escaped the week’s broader risk-off selling. Even a steady flow of capital-return announcements hasn’t shielded it from the pressure.

Kyle Rodda, senior market analyst at Capital.com, said markets are hoping the standoff ends up “self-limiting,” but he flagged the risk of “a potentially disruptive standoff” between the U.S. and the EU. Henry Cook, MUFG’s Europe economist, added that “tariff uncertainty will remain elevated,” even if tensions ease. Reuters

RELX dropped 2.6% on Monday, closing at 30.14 pounds and underperforming the FTSE 100’s modest 0.4% decline, according to MarketWatch data. The stock finished roughly 28% beneath its 52-week peak, with trading volume noticeably below recent averages.

RELX revealed in a stock exchange filing Monday that it purchased 307,528 shares via UBS, which it will hold in treasury. The volume-weighted average price was 3,040.9270 pence. Since January 2, the company has bought back 3.7 million shares.

A London Stock Exchange notice on Tuesday revealed that 55,000 RELX ordinary shares were admitted to trading through a block admission.

Buybacks mean a company is using cash to repurchase its own stock. These shares then become treasury stock, which the company can either cancel or hold onto for later use. Investors keep an eye on buybacks as a clue to a company’s cash flow and strategic priorities.

According to its Reuters profile, RELX offers analytics and decision tools centered on information across Risk, Scientific, Technical & Medical, Legal, and Exhibitions sectors.

The downside is straightforward: should tariff threats become reality and markets remain volatile, investors may slash holdings—even in reliable earners. A weak earnings report or a cautious outlook at the next update would only deepen the selling pressure.

RELX’s next major checkpoint is its full-year results for the period ending Dec. 31, set for release on Feb. 12. Investors will be watching closely for updated guidance and any new information on capital returns.

Stock Market Today

  • CSL Shares Rise 9.8% After FY26 Guidance Cut on Impairments and Channel Shifts
    June 13, 2026, 5:50 AM EDT. CSL (ASX:CSL) shares climbed 9.8% following a downward revision of its FY26 revenue and profit forecasts. The revision reflects impairments and writedowns linked to changes in U.S. immunoglobulin sales channels and weakening albumin prices in China. Despite these challenges, investor sentiment shows cautious optimism about CSL's operational turnaround prospects. The market now awaits CSL's full-year results and dividend update on 18 August 2026, which will offer clarity on revenue trends and any further impairments. CSL projects FY29 revenue of US$16.9 billion and earnings of US$3.3 billion, suggesting a potential 31% upside to current share prices. However, risks remain around sustained margin pressure and additional write-downs in plasma and albumin segments.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 13.06.2026

13 June 2026
LIVEMarkets rolling coverageStarted: June 13, 2026, 4:00 AM EDTUpdated: June 13, 2026, 5:52 AM EDT CSL Shares Rise 9.8% After FY26 Guidance Cut on Impairments and Channel Shifts June 13, 2026, 5:50 AM EDT. CSL (ASX:CSL) shares climbed 9.8% following a downward revision of its FY26 revenue and profit forecasts. The revision reflects impairments and writedowns linked to changes in U.S. immunoglobulin sales channels and weakening albumin prices in China. Despite these challenges, investor sentiment shows cautious optimism about CSL’s operational turnaround prospects. The market now awaits CSL’s full-year results and dividend update on 18 August 2026, which will offer
SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
Unilever share price today: ULVR slides in London as tariff nerves linger ahead of results
Previous Story

Unilever share price today: ULVR slides in London as tariff nerves linger ahead of results

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals
Next Story

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals

Go toTop